ciltacabtagene autoleucel
janssen
['multiplemyeloma']
#legendbiotech reported longer-term data from #cartitude program continue to show deep and durable responses with #ciltacabtageneautoleucel across lines of #therapy in patients with #multiplemyeloma #asco22 $legn 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.